Vivaik Tyagi, MD
Gastroenterology · Lancaster, CANPI 1073612545
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,085 of the $27,954 with a category attached, or 61.1%. Gilead accounts for 61.6% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2023 at $14,474 and has fallen 92.1% since, to $1,148 in 2025. Among gastroenterology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 450 payments — averaging $62.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$17K
- AbbVie$3K
- Nestle Healthcare Nutrition Inc.$2K
- Johnson & Johnson$946
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$780
- Takeda Pharmaceuticals U.S.A., Inc.$594
- plus $3K from 30 others
Across 94 payments — averaging $5532.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$447K
- Bausch Health US, LLC$62K
- Pfizer$12K
What the payments were for
- Speaking & faculty fees$17,08561%
- Travel & lodging$1,1764%
- Food & beverage$9,44634%
- Education$2121%
- Gifts$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 30 | $17,234 |
| AbbVie | 172 | $2,861 |
| Nestle Healthcare Nutrition Inc. | 3 | $2,160 |
| Johnson & Johnson | 50 | $946 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 41 | $780 |
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $594 |
| Endogastric Solutions, Inc | 4 | $347 |
| Boston Scientific | 8 | $288 |
| Pfizer | 13 | $274 |
| E.r. Squibb & Sons, L.L.C. | 2 | $267 |
| Sanofi | 9 | $247 |
| Ardelyx, Inc. | 12 | $224 |
| Ironwood Pharmaceuticals, Inc | 10 | $219 |
| Phathom Pharmaceuticals, Inc. | 4 | $208 |
| Tempus AI, Inc | 3 | $166 |
| Bristol Myers Squibb | 8 | $137 |
| Merck | 8 | $135 |
| Regeneron Healthcare Solutions, Inc. | 5 | $118 |
| Dova Pharmaceuticals | 1 | $97 |
| Evoke Pharma, Inc. | 5 | $83 |
| Braintree Laboratories, Inc. | 4 | $76 |
| Redhill Biopharma Inc. | 4 | $70 |
| Shionogi Inc | 3 | $69 |
| Madrigal Pharmaceuticals | 3 | $66 |
| Echosens North America, Inc. | 2 | $36 |
| Capsovision, Inc. | 2 | $34 |
| Ipsen Biopharmaceuticals, Inc | 1 | $32 |
| QOL Medical, LLC | 1 | $31 |
| AstraZeneca | 2 | $29 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $21 |
| Pinnacle Biologics, Inc | 1 | $21 |
| Intercept Pharmaceuticals, Inc. | 1 | $17 |
| Micro-tech Endoscopy USA, Inc. | 1 | $15 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,954 in reported general payments places this provider in the 90th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 219 | $155,042 |
| ZenpepLipase/Protease/Amylase | 20 | $87,222 |
| XifaxanRifaximin | 20 | $84,726 |
| RelistorMethylnaltrexone Bromide | 24 | $58,779 |
| MovantikNaloxegol Oxalate | 91 | $37,570 |
| IbsrelaTenapanor Hcl | 24 | $35,805 |
| TrulancePlecanatide | 31 | $23,546 |
| Lubiprostone | 47 | $8,455 |
| Pantoprazole Sodium | 792 | $7,940 |
| MotegrityPrucalopride Succinate | 13 | $6,963 |
| Mesalamine | 21 | $6,809 |
| Dexlansoprazole DrDexlansoprazole | 17 | $5,945 |
| Mesalamine ErMesalamine | 22 | $5,631 |
| Famotidine | 643 | $4,995 |
| Lactulose | 83 | $4,757 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Relistor, Trulance | $780 | $167,05275 claims |
| AbbVieLinzess | $2,861 | $155,042219 claims |
| Redhill Biopharma Inc.Movantik | $70 | $37,57091 claims |
| Ardelyx, Inc.Ibsrela | $224 | $35,80524 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $594 | $6,96313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,885 gastroenterology providers in California.
Other gastroenterology in Lancaster
- Jatinder PruthiLancaster$217K
- Bennett RothLos Angeles$2.8M
- Douglas NguyenMission Viejo$2M
- Sammy SaabLos Angeles$1.9M
- Kenneth ChangNewport Beach$1.3M
- Joo HwangStanford$1M
- Drew SchembreWalnut Creek$659K
- Quan Nhula Jolla$641K
- Sadeea AbbasiLos Angeles$556K
- Ali RezaieWest Hollywood$519K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.